MarketPR
A $178 million Ekterly monetization payment reached DRI Healthcare Trust (TSE: DHT.UN) on the morning of its Q2 earnings call, ahead of the mid-August window management had projected, freeing capital for a deployment cycle described as higher than usual.
The transaction generated a 1.5x return on invested capital and a high-20% internal rate of return.
The trust maintained its expectation of completing at least one new deal in the second half of 2026 and expects to begin collecting royalties from Lumvoa, its newly FDA-approved thyroid eye disease asset, starting in Q3.
Q2 by the numbers Total income rose 13% year over year to $50.1 million, with royalty income up 8% to $48.2 million.
Keep reading